| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3214182 | Journal of Dermatological Science | 2008 | 4 Pages |
Abstract
SummaryThe immunomodulator, AS101, inhibits production of IL-10, IL-4 and expression of p38 MAPK, while increasing production of IFNγ and IL-2. Together with its excellent clinical safety profile in humans, suggests a potential therapeutic use for AD.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Dvora Sredni-Kenigsbuch, Michael Shohat, Batia Shohat, Dan Ben-Amitai, Chi-Chao Chan, Michael David,